Carlos H Barcenas, M.D., M.Sc.
Department of Breast Medical Oncology, Division of Cancer Medicine
About Dr. Barcenas
Dr. Barcenas obtained his M.D. degree from the Pontiificia Universidad Javeriana in Bogota, Colombia in 1992. He specialized and practiced Occupational Medicine in Colombia until 1998. He then moved to Houston in 1999 and worked in the Department of Epidemiology at MD Anderson. He obtained a Master of Science degree in Epidemiology at The University of Texas School of Public Health in 2003. In 2009, he completed his training in the Internal Medicine Residency Program at the Medical College of Georgia, in Augusta. He then completed his Hematology-Medical Oncology Fellowship training at MD Anderson in June of 2013. He was appointed as Assistant Professor, Tenure Track, in the Department of Breast Medical Oncology at MD Anderson Cancer Center in July of 2013.
Read More
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Associate Medical Director, Breast Cancer Survivorship, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
Dr. Barcenas has a background in Epidemiology, and has worked in the field of Comparative Effectiveness and Health Outcomes Research, conducting various studies that have resulted in publications in several peer-reviewed journals. He has a strong research interest in Cancer Survivorship Research and has proposed studies designed to provide insight on environmental and genetic determinants of disease, to create risk prediction models, to assess the prevalence, mechanisms, risk factors and treatment of long-term treatment effects, with the ultimate purpose of enhancing the quality of life for cancer survivors.
Education & Training
Degree-Granting Education
| 2003 | University of Texas School of Public Health, Houston, TX, USA, M.Sc, Epidemiology |
| 1992 | Pontificia Universidad Javeriana, School of Medicine, Bogota, COL, MD, Medicine |
Postgraduate Training
| 2017-2018 | Faculty Development, The Heart of Leadership Program, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2010-2013 | Clinical Fellowship, Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2006-2009 | Clinical Internship, Internal Medicine, Medical College of Georgia, Augusta, GA |
| 1993-1997 | Specialist, Occupational Health, Universidad El Bosque, Bogotá |
Board Certifications
| 2013 | American Board of Internal Medicine - Medical Oncology |
| 2009 | American Board of Internal Medicine - Internal Medicine |
Experience & Service
Academic Appointments
Clinical Assistant Professor, Department of Medicine, Medical College of Georgia, Augusta, GA, 2009 - 2010
Administrative Appointments/Responsibilities
Quality Officer for Performance Improvement, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2016
Assistant Epidemiologist/Data Manager, Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999 - 2006
Occupational Medicine Physician, Colmena Riesgos Profesionales, Bogotá, 1995 - 1998
Institutional Committee Activities
Chair and Program Committee Member, Survivorship and Database Working Group, 2021 - Present
Member, Clinical Care Work Group, 2019 - 2023
Member, MD Anderson Cancer Network, 2019 - Present
Team Member, Survival Outcomes Steering Taskforce, 2019 - 2019
Team Member, EHR EPIC Multidisciplinary Team Meeting for the Breast Center, 2018 - 2020
Collaborator, Global Program Business Development to assess research projects in Colombia, South America, 2018 - 2021
Team Member, Oncology History Advisory Group Meeting, 2017 - 2017
Committee Member, Medical Record Committee Meeting, 2016 - Present
Committee Member, Breast Cancer Related Lymphedema Core Leadership, 2015 - 2017
Team Member, Follow up for Validation on Breast Outcome Measures with ICCI Team, 2014 - 2017
Committee Member, Pain and End of Life Project Committee, 2014 - 2016
Committee Member, Patient History Data Base Ad-hoc Committee, 2014 - 2016
Committee Member, Cancer Survivorship Research Advisory Workgroup, 2014 - 2023
Member, Integrative Health Working Group, 2014 - 2017
Chair and Committee Member, Breast Cancer Management System (BCMS) Database Development Committee, 2014 - Present
Committee Member, Breast Program Leadership Committee, 2014 - 2020
Chair and Program Committee Member, New Patient Tumor Board Peer Review Planning Meeting, 2014 - Present
Honors & Awards
| 2016 | Paul Calabresi Career Development Award for Clinical Oncology (NIH K-12), Paul Calabresi |
| 2016 | Distinguished Educator Award, Perspectives in Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center |
| 2013 | Annual Hematology and Oncology Fellowship Clinical Investigation Award, The University of Texas MD Anderson Cancer Center |
| 2013 | MD Anderson Fellowship Education Chief Academic Year 2012 - 2013, The University of Texas MD Anderson Cancer Center |
| 2013 | Allison and Brian Grove Endowed Fellowship |
| 2012 | Sheskey Family Fellowship for Breast Cancer Research Award |
| 2012 | Allison and Brian Grove Endowed Fellowship |
| 2011 | Allison and Brian Grove Endowed Fellowship |
| 2011 | Fellow CERCIT Fellowship Scholar |
| 2011 | ASCO Annual Meeting Merit Award, American Society of Clinical Oncology |
| 2009 | First Place Rahn-Peacock Research Award, Medical College of Georgia |
| 2009 | Nominated for Resident of the Year, Medical College of Georgia |
| 2005 | Performance Reward. Department of Epidemiology, The University of Texas MD Anderson Cancer Center |
| 1997 | Evaluation of audiometric interpretation scales for the early detection of neurosensory hypoacusis by noise: Student Award Presentation in the Fifth Institutional Research Meeting of Schools of Medicine, Bogotá, Colombia |
Selected Publications
Peer-Reviewed Articles
- Jackisch C, Barcenas CH, Bartsch R, Palma JD, Glück S, Harbeck N, Macedo G, O'Shaughnessy J, Pistilli B, Ruiz-Borrego M, Rugo HS. Optimal strategies for successful initiation of neratinib in patients with HER2-positive breast cancer. Clin Breast Cancer 21(5):e575-e583, 2021. e-Pub 2021. PMID: 33678567.
- Dumbrava EE, Call SG, Huang HJ, Stuckett AL, Madwani K, Adat A, Hong DS, Piha-Paul SA, Subbiah V, Karp DD, Fu S, Naing A, Tsimberidou AM, Moulder SL, Koenig KH, Barcenas CH, Kee BK, Fogelman DR, Kopetz ES, Meric-Bernstam F, Janku F. PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers. ESMO Open 6(5):100230, 2021. e-Pub 2021. PMID: 34479035.
- Elmore LC, Kuerer HM, Barcenas CH, Smith BD, Miggins MV, Lucci A, Caudle AS, Meric-Bernstam F, Hunt KK, Teshome M. Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Ann Surg Oncol 28(10):5477-5485, 2021. e-Pub 2021. PMID: 34247335.
- Kevin Diao,Lauren M Andring, Barcanas, C H; Singh, ; Le-Petross,H; Reed,V K; Reddy, J P; Bloom, E; Ahmad, N R; Mayo, L L; Perkins, G H; Mitchell, M P; Tereffe, W. Contemporary Outcomes after Multimodality Therapy in Breast Cancer Patients Presenting with Ipsilateral Supraclavicular Node Involvement. Red Journal (IJROBP), 2021.
- Barcenas CH, Song J, Murthy RK, Raghavendra AS, Li Y, Hsu L, Carlson RW, Tripathy D, Hortobagyi GN. Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer. JCO Clin Cancer Inform 5:789-804, 2021. PMID: 34351787.
- Singareeka Raghavendra A, Alameddine HF, Andersen CR, Selber JC, Brewster AM, Barcenas CH, Caudle AS, Arun BK, Tripathy D, Ibrahim NK. Influencers of the decision to undergo contralateral prophylactic mastectomy among women with unilateral breast cancer. Cancers (Basel) 13(9), 2021. PMID: 33922702.
- Asad S, Barcenas CH, Bleicher RJ, Cohen AL, Javid SH, Levine EG, Lin NU, Moy B, Niland J, Wolff AC, Hassett MJ, Stover DG. Socio demographic factors associated with rapid relapse in triple-negative breast cancer: A multi-institution study. J Natl Compr Canc Netw:1-8. e-Pub 2021. PMID: 33691275.
- Chun YS, Mizuno T, Cloyd JM, Ha MJ, Omichi K, Tzeng CD, Aloia TA, Ueno NT, Kuerer HM, Barcenas CH, Vauthey JN. Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. Eur J Surg Oncol 46(9):1588-1595, 2020. e-Pub 2020. PMID: 32253074.
- de Melo Gagliato D, Lei X, Giordano SH, Valero V, Barcenas CH, Hortobagyi GN, Chavez-MacGregor M. Impact of delayed neoadjuvant systemic chemotherapy on overall survival among breast cancer patients. Oncologist 25(9):749-757, 2020. e-Pub 2020. PMID: 32431013.
- Barcenas CH, Hurvitz SA, Di Palma JA, Bose R, Chien AJ, Iannotti N, Marx G, Brufsky A, Litvak A, Ibrahim E, Alvarez RH, Ruiz-Borrego M, Chan N, Manalo Y, Kellum A, Trudeau M, Thirlwell M, Garcia Saenz J, Hunt D, Bryce R, McCulloch L, Rugo HS, Tripathy D, Chan A, CONTROL Study Investigators. Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: CONTROL Trial. Ann Oncol 31(9):1223-1230, 2020. e-Pub 2020. PMID: 32464281.
- Berkman A, Livingston JD, Merriman JK, Hildebrandt M, Wang J, Dibaj SS, McQuade JL, You JQN, Ying AK, Barcenas CH, Bodurka E, Depombo A, Lee HJ, dee Grut JF, Roth M. Long-term survival among 5 years survivors of adolescent and young adult cancer. Cancer, 2020.
- Montoya-Restrepo M, Barcenas CH, Gomez-Wolf R, Cock-Rada A, Castano-Vasquez M, Garcia-Garcia H. Survival of young women with breast cancer in a Colombian referral Cancer Center between 2007-2016. Rev Col Hematol Oncol 7(1):26-32, 2020.
- Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant Talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. J Clin Oncol 38(5):JCO1901304, 2020. e-Pub 2019. PMID: 31461380.
- Chen E, Abu-Sbeih H, Thirumurthi S, Mallepally N, Khurana S, Wei D, Altan M, Morris VK, Tan D, Barcenas CH, Wang Y. Clinical characteristics of colitis induced by taxane-based chemotherapy. Ann Gastroenterol 33(1):59-67, 2020. e-Pub 2019. PMID: 31892799.
- Le Du F, Fujii T, Kida K, Davis DW, Park M, Liu DD, Wu W, Chavez-MacGregor M, Barcenas CH, Valero V, Tripathy D, Reuben JM, Ueno NT. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy. PLoS One 15(3):e0229903, 2020. e-Pub 2020. PMID: 32214335.
- Murthy RK, Song J, Raghavendra AS, Li Y, Hsu L, Hess KR, Barcenas CH, Valero V, Carlson RW, Tripathy D, Hortobagyi GN. Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. NPJ Breast Cancer 6:11, 2020. e-Pub 2020. PMID: 32219153.
- Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC, Giordano SH. Potentially inappropriate medications defined by STOPP criteria in older patients with breast and colorectal cancer. J Geriatr Oncol 10(5):705-708, 2019. e-Pub 2019. PMID: 30795923.
- Christopherson K, Lei X, Barcenas C, Buchholz TA, Garg N, Hoffman KE, Kuerer HM, Mittendorf E, Perkins G, Shaitelman SF, Smith GL, Stauder M, Strom EA, Tereffe W, Woodward WA, Smith BD. Outcomes of curative-intent treatment for breast cancer patients presenting with sternal or mediastinal involvement. Int J Radiat Oncol Biol Phys 104(3):574-581, 2019. e-Pub 2019. PMID: 30851348.
- Baez-Vallecillo L, Raghavendra AS, Hess KR, Barcenas CH, Moulder SL, Tripathy D, Valero V, Murthy RK. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Res Treat 176(1):227-234, 2019. e-Pub 2019. PMID: 30977027.
- Abu-Sbeih H, Ali FS, Ge PS, Barcenas CH, Lum P, Qiao W, Bresalier RS, Bhutani MS, Raju GS, Wang Y. Patients with breast cancer may be at higher risk of colorectal neoplasia. Ann Gastroenterol 32(4):400-406, 2019. e-Pub 2019. PMID: 31263363.
- Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT. A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment. Br J Cancer 120(12):1105-1112, 2019. e-Pub 2019. PMID: 31097774.
- Tevis SE, Bassett R, Bedrosian I, Barcenas CH, Black DM, Caudle AS, DeSnyder SM, Fitzsullivan E, Hunt KK, Kuerer HM, Lucci A, Meric-Bernstam F, Mittendorf EA, Park K, Teshome M, Thompson AM, Hwang RF. Oncotype DX recurrence score does not predict nodal burden in clinically node negative breast cancer patients. Ann Surg Oncol 26(3):815-820, 2019. e-Pub 2018. PMID: 30556120.
- Wong Y, Raghavendra AS, Hatzis C, Irizarry JP, Vega T, Horowitz N, Barcenas CH, Chavez-MacGregor M, Valero V, Tripathy D, Pusztai L, Murthy RK. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy. Oncologist 24(3):313-318, 2019. e-Pub 2018. PMID: 30139836.
- Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HM. Ductal carcinoma in situ and margins <2mm: Contemporary outcomes with breast conservation. Ann Surg 269(1):150-157, 2019. e-Pub 2017. PMID: 28742682.
- Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clin Breast Cancer 18(6):e1283-e1288, 2018. e-Pub 2018. PMID: 30077429.
- Stecklein SR, Park M, Liu DD, Valle Goffin JJ, Caudle AS, Mittendorf EA, Barcenas CH, Mougalian S, Woodward WA, Valero V, Sahin AA, Yang WT, Shaitelman SF. Long-term impact of regional nodal irradiation in patients with node-positive breast cancer treated with neoadjuvant systemic therapy. Int J Radiat Oncol Biol Phys 102(3):568-577, 2018. e-Pub 2018. PMID: 29928946.
- Karuturi MS, Holmes HM, Lei X, Johnson M, Barcenas CH, Cantor SB, Gallick GE, Bast RC, Giordano SH. Potentially inappropriate medication use in older patients with breast and colorectal cancer. Cancer 124(14):3000-3007, 2018. e-Pub 2018. PMID: 29689595.
- Barcenas CH, Shafaee MN, Sinha AK, Raghavendra A, Saigal B, Murthy RK, Woodson AH, Arun B. Genetic counseling referral rates in long-term survivors of triple-negative breast cancer. J Natl Compr Canc Netw 16(5):518-524, 2018. PMID: 29752326.
- Raghavendra A, Sinha AK, Valle-Goffin J, Shen Y, Tripathy D, Barcenas CH. Determinants of weight gain during adjuvant endocrine therapy and association of such weight gain with recurrence in long-term breast cancer survivors. Clin Breast Cancer 18(1):e7-e13. doi: 10.1016/j.clbc.2017.11.006, 2018. e-Pub 2017. PMID: 29239836.
- Reddy SM, Barcenas CH, Sinha AK, Hsu L, Moulder SL, Tripathy D, Hortobagyi GN, Valero V. Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. Br J Cancer 118(1):17-23, 2018. e-Pub 2017. PMID: 29235566.
- Fayanju OM, Hall CS, Bauldry JB, Karhade M, Valad LM, Kuerer HM, DeSnyder SM, Barcenas CH, Lucci A. Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. Am J Surg 214(4):666-671, 2017. e-Pub 2017. PMID: 28720217.
- Wu X, Ye Y, Barcenas CH, Chow WH, Meng QH, Chavez-MacGregor M, Hildebrandt MA, Zhao H, Gu X, Deng Y, Wagar E, Esteva FJ, Tripathy D, Hortobagyi GN. Personalized prognostic prediction models for breast cancer recurrence and survival incorporating multidimensional data. J Natl Cancer Inst 109(7):doi: 10.1093/jnci/djw314, 2017. PMID: 28376179.
- Barcenas CH, Raghavendra A, Sinha AK, Syed MP, Hsu L, Patangan MG, Chavez-MacGregor M, Shen Y, Hortobagyi GH, Valero V, Giordano SH, Ueno NT, Tripathy D. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay. Cancer 123(13):doi: 10.1002/cncr.30618, 2017. e-Pub 2017. PMID: 28199747.
- Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Identification of patients with documented pathologic complete response in the breast after neoadjuvant chemotherapy for omission of axillary surgery. JAMA Surg 152(7):doi: 10.1001/jamasurg.2017.0562, 2017. PMID: 28423171.
- Raghavendra A, Sinha AK, Le-Petross HT, Garg N, Hsu L, Patangan M, Bevers TB, Shen Y, Banu A, Tripathy D, Bedrosian I, Barcenas CH. Mammographic breast density is associated with the development of contralateral breast cancer. Cancer 123(11):1935-1940, 2017. e-Pub 2017. PMID: 28135395.
- Cropper C, Woodson A, Arun B, Barcenas C, Litton J, Noblin S, Liu D, Park M, Daniels M. Evaluating the NCCN clinical criteria for recommending BRCA1 and BRCA2 genetic testing in patients with breast cancer. J Natl Compr Canc Netw 15(6):797-803, 2017. PMID: 28596260.
- Sinha AK, Patel JR, Shen Y, Ueno NT, Giordano SH, Tripathy D, Lopez DS, Barcenas CH. Location of receipt of initial treatment and outcomes in long-term breast cancer survivors. PLoS One 12(1):e017008. doi: 10.1371/jornal.pone.01790081, 2017. e-Pub 2017. PMID: 28085940.
- Kuerer HM, Smith BD, Chavez-MacGregor M, Albarracin C, Barcenas CH, Santiago L, Edgerton ME, Rauch GM, Giordano SH, Sahin A, Krishnamurthy S, Woodward W, Tripathy D, Yang WT, Hunt KK. DCIS margins and breast conservation: MD Anderson Cancer Center Multidisciplinary Practice Guidelines and Outcomes. J Cancer 8(14):2653-2662, 2017. e-Pub 2017. PMID: 28928852.
- Fujii T, Reuben JM, Huo L, Espinosa Fernandez JR, Gong Y, Krupa R, Suraneni MV, Graf RP, Lee J, Greene S, Rodriguez A, Dugan L, Louw J, Lim B, Barcenas CH, Marx AN, Tripathy D, Wang Y, Landers M, Dittamore R, Ueno NT. Androgen receptor expression on circulating tumor cells in metastatic breast cancer. PLoS One 12(9):e0185231, 2017. e-Pub 2017. PMID: 28957377.
- Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, Piwnica-Worms H, Arun BK. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. NPJ Breast Cancer 3:49, 2017. e-Pub 2017. PMID: 29238749.
- Fayanju OM, Mayo TL, Spinks TE, Lee S, Barcenas CH, Smith BD, Giordano SH, Hwang RF, Ehlers RA, Selber JC, Walters R, Tripathy D, Hunt KK, Buchholz TA, Feeley TW, Kuerer HM. Value-based breast cancer care: Multidisciplinary approach for defining patient-centered outcomes. Ann Surg Oncol 23(8):2385-90, 2016. e-Pub 2016. PMID: 26979306.
- Edwards BJ, Sun M, West DP, Guindani M, Lin YH, Lu H, Hu M, Barcenas C, Bird J, Feng C, Saraykar S, Tripathy D, Hortobagyi GN, Gagel R, Murphy WA. Incidence of atypical femur fractures in cancer patients: The MD Anderson Cancer Center Experience. J Bone Miner Res 31(8):1569-76, 2016. e-Pub 2016. PMID: 26896384.
- Sanford RA, Lei X, Barcenas CH, Mittendorf EA, Caudle AS, Valero V, Tripathy D, Giordano SH, Chavez-MacGregor M. Impact of time from completion of neoadjuvant chemotherapy to surgery on survival outcomes in breast cancer patients. Ann Surg Oncol 23(5):1515-21, 2016. e-Pub 2015. PMID: 26678405.
- Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, Valero V, Shen Y, Ueno NT. Effectiveness of an adjuvant chemotherapy regimen for early-stage breast cancer: A systematic review and network meta-analysis. JAMA Oncol 1(9):1311-8, 2015. PMID: 26402167.
- Barcenas CH, Niu J, Zhang N, Zhang Y, Buchholz TA, Elting LS, Hortobagyi GN, Smith BD, Giordano SH. Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol 32(19):2010-7, 2014. PMID: 24868022.
- Delpech Y, Coutant C, Hsu L, Barranger E, Iwamoto T, Barcenas CH, Hortobagyi GN, Rouzier R, Esteva FJ, Pusztai L. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas. Br J Cancer 108(2):285-91, 2013. PMID: 23299541.
- Barcenas CH, Zhang N, Zhao H, Duan Z, Buchholz TA, Hortobagyi GN, Giordano SH. Anthracycline regimen adherence in older patients with early breast cancer. Oncologist 17(3):303-11, 2012. PMID: 22371383.
- Barcenas CH, Wells J, Chong D, French J, Looney SW, Samuel TA. Race as an independent risk factor for breast cancer survival: Breast cancer outcomes from the Medical College of Georgia tumor registry. Clin Breast Cancer 10(1):59-63, 2010. PMID: 20133260.
- Hernández-Valero MA, Wilkinson AV, Forman MR, Etzel CJ, Cao Y, Bárcenas CH, Strom SS, Spitz MR, Bondy ML. Maternal BMI and country of birth as indicators of childhood obesity in children of Mexican origin. Obesity (Silver Spring) 15(10):2512-9, 2007. PMID: 17925478.
- Mullen JT, Rodriguez-Bigas MA, Chang GJ, Barcenas CH, Crane CH, Skibber JM, Feig BW. Results of surgical salvage after failed chemoradiation therapy for epidermoid carcinoma of the anal canal. Ann Surg Oncol 14(2):478-83, 2007. PMID: 17103253.
- Barcenas CH, Wilkinson AV, Strom SS, Cao Y, Saunders KC, Mahabir S, Hernández-Valero MA, Forman MR, Spitz MR, Bondy ML. Birthplace, years of residence in the United States, and obesity among Mexican-American adults. Obesity (Silver Spring) 15(4):1043-52, 2007. PMID: 17426341.
- Barcenas CH, Hosain GM, Arun B, Zong J, Zhou X, Chen J, Cortada JM, Mills GB, Tomlinson GE, Miller AR, Strong LC, Amos CI. Assessing BRCA carrier probabilities in extended families. J Clin Oncol 24(3):354-60, 2006. PMID: 16421416.
- Wilkinson AV, Hernández-Valero MA, Etzel CJ, Barcenas CH, Spitz MR, Bondy ML, Strom SS. Self-rated health among adult women of Mexican origin. Hisp J Behav Sci 28(1):127-142, 2006. PMID: 24600161.
- Wilkinson AV, Spitz MR, Strom SS, Prokhorov AV, Barcenas CH, Cao Y, Saunders KC, Bondy ML. Effects of nativity, age at migration, and acculturation on smoking among adult Houston residents of Mexican descent. Am J Public Health 95(6):1043-9, 2005. PMID: 15914831.
- Barcenas CH, Delclos GL, El-Zein R, Tortolero-Luna G, Whitehead LW, Spitz MR. Wood dust exposure and the association with lung cancer risk. Am J Ind Med 47(4):349-57, 2005. PMID: 15776474.
Invited Articles
- Sinha AK, Moye L, Piller LB, Yamal JM, Barcenas CH, Lin J, Davis BR. Adaptive group-sequential design with population enrichment in phase 3 randomized controlled trials with two binary co-primary endpoints. Stat Med 38(21):3985-3996, 2019. e-Pub 2019. PMID: 31184783.
Manuals, Teaching Aids, Other Teaching Publications
- Barcenas CH. NEJM Knowledge+. Writer of board-style “Questions and Answers in Medical Oncology for Primary Care Physicians”. New England Journal of Medicine, 2013.
Other Articles
- Barcenas CH, Olek E, Hunt D, et al. Loperamide regimen may reduce diarrhea in Neratinib-treated patients. Today's UT MD Anderson Cancer Center News Oncology, Public Relations Nurse Advisor, 2016.
Editorials
- Barcenas C. Commentary on: Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. Breast Diseases: A Year Book Quarterly 27(1):1-3, 2016.
- Barcenas CH. Commentary on: Impact of adjuvant chemotherapy on long-term employment of survivors of early-stage breast cancer. Breast Diseases: A Year Book Quarterly 26(1):90-92, 2015.
- Barcenas C. Commentary on: Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. Breast Diseases: A Year Book Quarterly 26:210-211, 2015.
Book Chapters
- Barcenas CH, Ibrahim NK. Chemotherapy induced colitis. In: Colitis. In-Tech - Open Access Publishing: New York, 115-128, 2012.
- Barcenas CH, Brewster AM. Overview of breast cancer survivorship management guidelines. In: Breast Cancer. 3rd. Springer: New York.
Letters to the Editor
- Zhang X, Sun M, McKoy JM, Bhulani NNA, Valero V, Barcenas CH, Popat UR, Sri MK, Shah JB, Dinney CP, Hedberg AM, Champlin R, Tripathy D, Holmes HM, Stroehlein JR, Edwards BJ. Malnutrition in older patients with cancer: Appraisal of the Mini Nutritional Assessment, weight loss, and body mass index. J Geriatr Oncol 9: 81-83, 2018.
Grant & Contract Support
| Title: | CERCIT Scholar in the comparative effectiveness research on cancer in Texas (CERCIT) Training Program |
| Funding Source: | CERCIT |
| Role: | Principal Investigator |
| Title: | T32 Academic Fellowship training grant for academic years 2011 through 2013 |
| Funding Source: | NIH/NCI |
| Role: | Trainee |
| Title: | Calabresi Clinical Oncology Scholar K12 Award (Clinical Investigator Program) |
| Funding Source: | Paul Calabresi Clinical Oncology |
| Role: | Principal Investigator |
| Title: | An Open-Label to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis |
| Funding Source: | Puma Biotechnology, Inc |
| Role: | Principal Investigator |
| Title: | DROPLET-BRC study |
| Funding Source: | Preferred Medicine, Inc |
| Role: | Principal Investigator |
| Title: | TrAstuzumab Cardiomyopathy Therapeutic Intervention with Carvedilol (TACTIC) Trial |
| Funding Source: | Mayo Clinic |
| Role: | Investigator |
| Title: | Detection of minimal residual disease (MR) in patients with breast cancer using a highly sensitive liquid biopsy platform and its association with clinical outcomes |
| Funding Source: | Personalis, Inc |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified August 12, 2024